JUL
19

The CLEAR-III World Cup Competition

World Cup ChampionsJuly 1st is the start of the 4th fiscal year for the CLEAR-III trial (the first patient enrolled in Sep-2009). And this year we are introducing a new friendly competition called the CLEAR-III World Cup. Similar to international soccer competitions, regional groups of 3 to 5 clinical sites will be organized into teams. The teams will score points based on achieving certain performance goals such as having a randomization, resolving queries promptly, or completing a patient visit within the expected visit window.

The idea for this unique and exciting competition came from from one of the BIOS Reading Center staff, Sam Tak. Sam has created a wonderful new opportunity to enhance internal collaboration at sites and to foster camaraderie among the trial sites. Of course, we'll use our VISION-EDC system to track each teams scores on a real-time basis.

Continue reading
  4607 Hits
4607 Hits
FEB
21

Bedside worksheets Updated - Redoux

Perfection can be an elusive goal, but one we are always pursuing here at the coordinating center. After our recent update of the bedside worksheets, someone found another obscure error. It's minor but to eliminate any potential confusion, we've corrected it anyway. A new version of the worksheets is now available for download.

Continue reading
  5476 Hits
5476 Hits
FEB
03

MISTIE Treatment Success at University of Kansas

Dr. Paul Camarata, a neurosurgeon and investigator for the MISTIE trial, was interviewed today about the successful treatment of a patient at the University of Kansas Medical CenterMIS stands for minimally-invasive surgery and is the technique used to place a catheter into the patient's intracerebral hematoma. (ICH, also called intracerebral hemorrhage, is a type of stroke caused by bleeding in the brain). A drug called tissue plasminogen activator (tPA) is then administered into this catheter for 1 to 3 days to breakup the blood clot (by enhancing a natural process called thrombolysis) so it can be drained out of the catheter.

Continue reading
  6277 Hits

Copyright

© WDAF (Fox Affiliate, Channel 4, Kansas City)

6277 Hits
FEB
02

International Stroke Conference 2012 - Daniel Hanley's Presentation on MISTIE Phase II Results

Dr. Daniel F. Hanley presented the results of the MISTIE Phase II trial today at the International Stroke Conference (ISC) in New Orleans. A copy of the abstract, presentation slides and the video are available in this article (click CONTINUE READING for the full article). Also, be sure to see Gayane Yenokyan's recent presentation to the CLEAR III investigators and coordinators on the preliminary outcomes data.

MISTIE Phase II Results: Safety, Efficacy and Surgical Performance

Background: We report the primary clinical outcome results (180 day mRS) for the “Minimally Invasive Surgery plus t-PA for Intracerebral Hemorrhage Evacuation” (MISTIE) trial, a NINDS-funded, two-stage, study of safety, efficacy, and surgical performance that continued to completion after a planned interim analysis showed a strong indication of safety, and efficacy.

Continue reading
  13495 Hits
Tags:
13495 Hits
FEB
01

The MISTIE III grant has been submitted!

After a tremendous effort over several months by all of the staff at the Johns Hopkins BIOS (Brain Injury Outcomes) coordinating center as well as the coordinators and investigators at over 35 investigational sites, we are happy to announce that a grant application has been submitted to the National Institute of Neurological Disorders and Stroke (NINDS, part of the National Institute of Health or NIH) requesting funding for the next phase in the MISTIE clinical development program.

Continue reading
  9697 Hits
9697 Hits

MISTIE-3 Site Locations